Status:
WITHDRAWN
Influence of Fampridine on Working Memory in Healthy Subjects
Lead Sponsor:
Prof. Dominique de Quervain, MD
Collaborating Sponsors:
Clinical Trial Unit, University Hospital Basel, Switzerland
University Hospital, Basel, Switzerland
Conditions:
Working Memory
Eligibility:
All Genders
18-30 years
Phase:
PHASE2
Brief Summary
Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants. The hypotheses is that fampridine improves working memory performance.
Eligibility Criteria
Inclusion
- male or female
- generally healthy
- normotensive (BP between 90/60 mmHg and 140/90 mmHg)
- BMI between 19 and 29,9 kg/m2
- aged between 18 and 30 years
- fluent German-speaking
- Informed consent as documented by signature
Exclusion
- contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine
- use of potassium channel blockers within the last 3 months
- concomitant treatment with OCT 2 inhibitors (e.g. cimetidine, propranolol)
- acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform disorder, suicidal tendency)
- acute cerebrovascular condition
- history of seizures
- risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse)
- renal impairment
- history of malignant cancers
- walking problems (e.g. due to dizziness)
- other clinically significant concomitant disease states (e.g. hepatic dysfunction, cardiovascular disease, diabetes, asthma)
- clinically significant laboratory or ECG abnormality that could be a safety issue in the study
- known or suspected non-compliance
- drug or alcohol abuse
- inability to follow the procedures of the study, e.g. due to language or psychological problems of the participant
- participation in another study with an investigational drug within the 30 days preceding and during the present study
- prior participation (less than two years ago) in a study investigating working memory (notably the n-back task)
- enrolment of the investigator, his/her family members, employees and other dependent persons
- smoking (\>3 cigarettes per day)
- intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics)
- pregnancy or breast feeding
Key Trial Info
Start Date :
January 1 2040
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2041
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04516603
Start Date
January 1 2040
End Date
December 31 2041
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Basel, Transfaculty Research Platform
Basel, Canton of Basel-City, Switzerland, 4055